Literature DB >> 10638449

Histopathologic grading of ovarian carcinoma: a review and proposal.

S G Silverberg1.   

Abstract

The histopathologic grade of ovarian epithelial carcinoma has generally been found to be of prognostic significance, but the grading system used has varied among published reports, and often has not been specified at all. The major proposed grading systems are reviewed, and a new system is proposed, which is modeled on the Nottingham system of breast cancer grading and is designed to be applied to all invasive epithelial carcinomas of the ovary. Results obtained in studies using this system are presented. When grading is compared with histopathologic typing of ovarian carcinoma, the latter is less valuable in predicting survival but better at predicting tumor responsiveness to chemotherapy, and can also suggest the chemotherapeutic agents to be used. Thus, both grade and type should be specified in the surgical pathology report for any ovarian carcinoma.

Entities:  

Mesh:

Year:  2000        PMID: 10638449     DOI: 10.1097/00004347-200001000-00003

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  82 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

Review 2.  Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors:  Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

Review 3.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 4.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

Review 5.  [Histological grading of epithelial ovarian cancer. Review and recommendation].

Authors:  S Hauptmann; A du Bois; I Meinhold-Herlein; J Pfisterer; S Avril
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

6.  Recent progress in the diagnosis and treatment of ovarian cancer.

Authors:  Danijela Jelovac; Deborah K Armstrong
Journal:  CA Cancer J Clin       Date:  2011-04-26       Impact factor: 508.702

7.  Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).

Authors:  Stefan Kommoss; Dietmar Schmidt; Friedrich Kommoss; Juergen Hedderich; Philipp Harter; Jacobus Pfisterer; Andreas du Bois
Journal:  Virchows Arch       Date:  2009-01-27       Impact factor: 4.064

8.  Promoter methylation and downregulated expression of the TBX15 gene in ovarian carcinoma.

Authors:  Gaia Gozzi; Sonia T Chelbi; Paola Manni; Loredana Alberti; Sergio Fonda; Sara Saponaro; Luca Fabbiani; Francesco Rivasi; Jean Benhattar; Lorena Losi
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

9.  Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters.

Authors:  Friederike Hoellen; Athina Kostara; Thomas Karn; Uwe Holtrich; Ahmed El-Balat; Mike Otto; Achim Rody; Lars C Hanker
Journal:  Mol Clin Oncol       Date:  2016-08-17

10.  Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.

Authors:  Anne-Katrin Zimmermann; Jochen Imig; Agnes Klar; Christoph Renner; Dimitri Korol; Daniel Fink; Sylvia Stadlmann; Gad Singer; Alexander Knuth; Holger Moch; Rosmarie Caduff
Journal:  Virchows Arch       Date:  2013-03-26       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.